Editor’s note: This is a developing news story. Please check back soon for updates.
Harrow acquired the U.S. commercial rights for Byqlovi through a licensing agreement with Formosa Pharmaceuticals, according to a press release.
The FDA approved Byqlovi (clobetasol propionate ophthalmic suspension 0.05%) for the treatment of inflammation and pain after ocular surgery in 2024.
The high-potency ophthalmic corticosteroid delivers “a highly uniform suspension” and minimizes particle setting with the help of Formosa’s APNT nanoparticle formulation technology, according to the